Alexion Pharmaceuticals Inc., of Boston, reported second-quarter revenues of $1.2 billion, a 15% increase compared to $1 billion in the same period last year. Net sales of Soliris (eculizumab), which recently gained a label expansion to treat neuromyelitis optica spectrum disorder in adults who are anti-aquaporin-4 antibody-positive, were $980.8 million in the quarter compared to $898.2 million in the second quarter of 2018, for a 9% increase, while volume increased 17% year-over-year. Strensiq (asfotase alfa) achieved $141.3 million in second-quarter sales compared to $125.1 million in the same period in 2018, for a 13% increase; volume increased 21% year-over-year. Kanuma (sebelipase alfa) sales were $26.2 million compared to $21.4 million a year earlier, for a 22% increase, while volume grew 33% year-over-year. Net sales of Ultomiris (ravulizumab-cwvz), approved in December 2018, were $54.2 million in the second quarter. On a GAAP basis, diluted earnings per share (EPS) for the quarter were $2.04, a 200% increase over a loss of $2.05 in the second quarter of 2018, which included $803.7 million in expenses related to the acquisition of Wilson Therapeutics AB. Alexion reported cash and equivalents of $2 billion as of June 30 compared to $1.4 billion a year earlier. The company increased guidance for its 2019 revenues to a range of $4.75 billion to $4.8 billion, from the $4.675 billion to $4.75 billion guided in April, and its full-year EPS on a GAAP basis to $8.13 to $8.41 from its April guidance of $6.76 to $7.96. On Wednesday, Alexion's shares (NASDAQ:ALXN) fell $1.45 to close at $120.97. (See BioWorld, Dec. 24, 2018, June 28, 2019, and July 1, 2019.)

No Comments